SCHEMBL5089286

SCHEMBL5089286

O=[N+]([O-])c1ccc(NCCN(c2nc(-c3ccc(Cl)cc3Cl)ccc2[N+](=O)[O-])N(CCNc2ccc([N+](=O)[O-])cn2)c2nc(-c3ccc(Cl)cc3Cl)ccc2[N+](=O)[O-])nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.53
MAPT P10636 3/20 0.45
NPC1 O15118 2/20 0.45
ALDH1A1 P00352 2/20 0.45
RAB9A P51151 2/20 0.45
GAA P10253 1/20 0.45
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
PIK3CG P48736 1/20 0.44
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
GSK3A P49840 3/20 0.43
CDK1 P06493 2/20 0.43
CCNB2 O95067 1/20 0.43
CCNB1 P14635 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
AHR P35869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7250443 0.86 GSK3B (0.56) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL6086880 0.84 GSK3B (0.57) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL7026093 0.80 GSK3B (0.63) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL6069510 0.79 GSK3B (0.51) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL6069118 0.78 GSK3B (0.56) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL6069852 0.76 MAPT (0.56) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL5094448 0.75 GSK3B (0.73) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL4393584 0.74 GSK3B (0.55) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL6086723 0.74 GSK3B (0.68) GSK3BMAPTNPC1ALDH1A1RAB9A
SCHEMBL5082606 0.73 GSK3B (0.55) GSK3BMAPTNPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425557-B2 Inhibitors of glycogen synthase kinase 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-16 US disclosed
US-7045519-B2 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-05-16 US disclosed
US-7037918-B2 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-05-02 US disclosed
US-20060089369-A1 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-04-27 US disclosed
EP-1087963-B1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORP (US) 2004-08-25 EP disclosed
US-6489344-B1 FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT CHIRON CORPORATION 2002-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089369-A1 Inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB GSK3B 1/4885MAPT 146/4885NPC1 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.